April 14, 2010 (FinancialWire) — Perrigo Co. (NASDAQ: PRGO) and Graceway Pharmaceuticals, LLC. said they have entered into an agreement to settle all existing patent litigation regarding Perrigo's ANDA filing No. 78-837 or generic imiquimod.

As part of this agreement, Perrigo will be named Graceway's authorized generic distributor for the Aldara product through February 24, 2011 and, under certain circumstances, will be able to launch its own generic product after that date.

Perrigo said it will begin shipping the authorized generic product within the next few weeks.

Aldara Cream 5% is indicated for the topical treatment of actinic keratoses on the face or scalp, superficial basal cell carcinoma, and external genital and perianal warts in patients 12 years old or older.

Perrigo said that the drug had sales of around $370 million for the 12 months ended February 2010, as measured by Wolters Kluwer Health.

Michigan-based Perrigo is a healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients and consumer products.  

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [nwdlsldw] [ltgnltgn]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.